Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX -2011 and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer


Evaluate the efficacy, as measured by overall response rate (ORR), following treatment with JTX-2011 administered in sequence with ipilimumab in subjects with NSCLC or urothelial cancer

Study Arms

  • Experimental LM1: Vopratelimab, Ipilimumab
  • Experimental LT1: Vopratelimab, Ipilimumab
  • Experimental UM1: Vopratelimab, Ipilimumab
  • Experimental UT1: Vopratelimab, Ipilimumab


  • Locally advanced, inoperable or metastatic NSCLC or urothelial cancer, with evaluable or measurable disease, according to RECIST v1.1, with at least one measurable lesion
  • Prior treatment with a PD-1/PD -L1 inhibitor for at least 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1